Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma.

Sarcoma

Sarcoma
II
Keedy, Vicki
NCT04044768
VICCSAR1948


Safety and Feasibility Study of Chimeric Antigen Receptor (CAR) T Cell Therapy with YESCARTA in the Outpatient Setting

Lymphoma

Lymphoma
N/A
Oluwole, Olalekan
NCT05108805
VICCCTT2109

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Multiple Cancer Types

Pediatric Leukemia, Pediatrics
III
Zarnegar-Lumley, Sara
NCT03959085
COGAALL1732



Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Multiple Cancer Types

Pediatrics, Wilms / Other Kidney (Pediatrics)
II
Benedetti, Daniel
NCT04322318
COGAREN1921

A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

Multiple Cancer Types

Pediatric Leukemia, Pediatrics
II
Zarnegar-Lumley, Sara
NCT04546399
COGAALL1821


Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

Multiple Cancer Types

Pediatrics, Sarcoma
II
Borinstein, Scott
NCT04388839
VICCPED2134

To learn more about any of our clinical
trials, call 615-936-8422.